Justice Department Investigating Aegerion Over Marketing Of New Cholesterol Drug

Aegerion Pharmaceuticals disclosed today that it is being investigated by the US Department of Justice over its marketing of Juxtapid (lomitapide). The drug was approved in December 2012 to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The drug costs $250,000 a year. The approval came with a box warning about the risk of hepatotoxicity and a strict Risk Evaluation and Mitigation Strategy (REMS) Program which requires certification of health care providers and pharmacies before the drug can be prescribed and dispensed.

Last November the company received a warning letter from the FDA after Aegerion’s CEO, Mark Beer, made comments on CNBC improperly promoting the drug.

Click here to read the full post on Forbes.

 

 

Leave a Reply

%d bloggers like this: